Mylan's EpiPen sales plummet as pricing scandal bites back
admin 6th November 2017 Uncategorised 0For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan’s third-quarter results. The now-infamous EpiPen took a $245 million hit to sales, partly on higher rebates required by a Justice Department settlement.
More: Mylan's EpiPen sales plummet as pricing scandal bites back
Source: fierce